OBJECTIVE: To describe in detail the diagnosis and clinical course of an unselected population-based cohort of patients with newly diagnosed bladder neoplasms. MATERIAL AND METHODS: A total of 538 patients registered in the Stockholm region with newly diagnosed primary bladder neoplasms (transitional cell carcinomas) in 1995 and 1996 were followed for at least 5 years. All hospitals and urology units in the region participated in the study. Treatment and follow-up were performed according to a standard-of-care programme. Routine pathological reports were used. Original case records were scrutinized on location in 2001. In addition, a tumour bank of freshly frozen tumour tissue was established. RESULTS: The calculated 5-year cancer-specific survival rate for the 538 patients in the cohort was 78%. No patient (0/29) with TaG1 tumours showed progression or died of bladder cancer. Only 2/187 patients (1%) with stage Ta and grade 2A or 2B tumours died of bladder cancer. In contrast, after 5 years of follow-up, patients with TaG3 and T1G2B tumours had disease-specific death rates of 20% and 27%, respectively. The result of the first cystoscopy examination after the initial resection of non-invasive tumours was of prognostic value. Recurrent disease was present in 62% (248/402) of all patients with Ta and T1 tumours at diagnosis and patients with T1 tumours had recurrences earlier than those with Ta tumours. Moreover, 32% (35/110) of the patients who presented with T1 tumours at diagnosis progressed to muscle-invasive disease during the follow-up period. The overall prognosis for patients presenting with muscle-invasive tumours (T2+) was dismal, with 69% (80/116) of the patients dying of the disease. CONCLUSIONS: We analysed a population-based cohort of patients with urinary bladder neoplasms in order to establish a clearly defined and unselected clinical series, with the main aims of comparing and evaluating the clinical utility of new molecular biology techniques. In the present series, TaG1 tumours behaved benignly. The disease-specific mortality rate was low for initial TaG2 tumours, intermediate for initial TaG3 and T1 tumours and high for initial T2+ tumours.
OBJECTIVE: To describe in detail the diagnosis and clinical course of an unselected population-based cohort of patients with newly diagnosed bladder neoplasms. MATERIAL AND METHODS: A total of 538 patients registered in the Stockholm region with newly diagnosed primary bladder neoplasms (transitional cell carcinomas) in 1995 and 1996 were followed for at least 5 years. All hospitals and urology units in the region participated in the study. Treatment and follow-up were performed according to a standard-of-care programme. Routine pathological reports were used. Original case records were scrutinized on location in 2001. In addition, a tumour bank of freshly frozen tumour tissue was established. RESULTS: The calculated 5-year cancer-specific survival rate for the 538 patients in the cohort was 78%. No patient (0/29) with TaG1 tumours showed progression or died of bladder cancer. Only 2/187 patients (1%) with stage Ta and grade 2A or 2B tumours died of bladder cancer. In contrast, after 5 years of follow-up, patients with TaG3 and T1G2B tumours had disease-specific death rates of 20% and 27%, respectively. The result of the first cystoscopy examination after the initial resection of non-invasive tumours was of prognostic value. Recurrent disease was present in 62% (248/402) of all patients with Ta and T1 tumours at diagnosis and patients with T1 tumours had recurrences earlier than those with Ta tumours. Moreover, 32% (35/110) of the patients who presented with T1 tumours at diagnosis progressed to muscle-invasive disease during the follow-up period. The overall prognosis for patients presenting with muscle-invasive tumours (T2+) was dismal, with 69% (80/116) of the patients dying of the disease. CONCLUSIONS: We analysed a population-based cohort of patients with urinary bladder neoplasms in order to establish a clearly defined and unselected clinical series, with the main aims of comparing and evaluating the clinical utility of new molecular biology techniques. In the present series, TaG1 tumours behaved benignly. The disease-specific mortality rate was low for initial TaG2 tumours, intermediate for initial TaG3 and T1 tumours and high for initial T2+ tumours.
Authors: Ashish M Kamat; J Alfred Witjes; Maurizio Brausi; Mark Soloway; Donald Lamm; Raj Persad; Roger Buckley; Andreas Böhle; Marc Colombel; Joan Palou Journal: J Urol Date: 2014-03-25 Impact factor: 7.450
Authors: Thorunn Rafnar; Sita H Vermeulen; Patrick Sulem; Gudmar Thorleifsson; Katja K Aben; J Alfred Witjes; Anne J Grotenhuis; Gerald W Verhaegh; Christina A Hulsbergen-van de Kaa; Soren Besenbacher; Daniel Gudbjartsson; Simon N Stacey; Julius Gudmundsson; Hrefna Johannsdottir; Hjordis Bjarnason; Carlo Zanon; Hafdis Helgadottir; Jon Gunnlaugur Jonasson; Laufey Tryggvadottir; Eirikur Jonsson; Gudmundur Geirsson; Sigfus Nikulasson; Vigdis Petursdottir; D Timothy Bishop; Sei Chung-Sak; Ananya Choudhury; Faye Elliott; Jennifer H Barrett; Margaret A Knowles; Petra J de Verdier; Charlotta Ryk; Annika Lindblom; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Paolo Vineis; Silvia Polidoro; Simonetta Guarrera; Carlotta Sacerdote; Angeles Panadero; José I Sanz-Velez; Manuel Sanchez; Gabriel Valdivia; Maria D Garcia-Prats; Jan G Hengstler; Silvia Selinski; Holger Gerullis; Daniel Ovsiannikov; Abdolaziz Khezri; Alireza Aminsharifi; Mahyar Malekzadeh; Leonard H van den Berg; Roel A Ophoff; Jan H Veldink; Maurice P Zeegers; Eliane Kellen; Jacopo Fostinelli; Daniele Andreoli; Cecilia Arici; Stefano Porru; Frank Buntinx; Abbas Ghaderi; Klaus Golka; José I Mayordomo; Giuseppe Matullo; Rajiv Kumar; Gunnar Steineck; Anne E Kiltie; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson; Lambertus A Kiemeney Journal: Hum Mol Genet Date: 2011-07-12 Impact factor: 6.150
Authors: Carlotta Sacerdote; Simonetta Guarrera; Fulvio Ricceri; Barbara Pardini; Silvia Polidoro; Alessandra Allione; Rossana Critelli; Alessia Russo; Angeline S Andrew; Yuanqing Ye; Xifeng Wu; Lambertus A Kiemeney; Andrea Bosio; Giovanni Casetta; Giuseppina Cucchiarale; Paolo Destefanis; Paolo Gontero; Luigi Rolle; Andrea Zitella; Dario Fontana; Paolo Vineis; Giuseppe Matullo Journal: Int J Cancer Date: 2013-04-25 Impact factor: 7.396
Authors: K T Kelsey; T Hirao; A Schned; S Hirao; T Devi-Ashok; H H Nelson; A Andrew; M R Karagas Journal: Br J Cancer Date: 2004-04-19 Impact factor: 7.640